BCL2 and acute myeloid leukemia: The first generation BCL-2 inhibitor ABT-737 induced apoptosis in AML-derived cell lines, in primary blasts, and in phenotypically defined AML stem cells; inhibited the growth of clonogenic AML progenitor cells; and was effective in reducing the leukemia burden in vivo in mice models of AML [32,33].